DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01460069

CompletedPhase NA

The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis

The Effect of GLP-1 in Psoriasis

Assets

GLP-1 / incretin class catch-all / Liraglutide

Listed sites

1

Recruiting sites

—

Enrollment

20

estimated

Study population

Obesity / overweight, Psoriasis / psoriatic arthritis

Key I/E criterion

•BMI ≥27

Primary endpoints

•PASI•DLQI

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01460069
Org study ID2011-000571-13

Timeline

Milestones

Study first posted2011-10-26estimated
Last update posted2013-06-21estimated
Study start2011-10 (month precision)
Primary completion2013-05actual (month precision)
Study completion2013-05actual (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-allLiraglutide

Study populations

Who this study enrolls

Obesity / overweightPsoriasis / psoriatic arthritis

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Caucasians above 18 years of age
•Plaque psoriasis
•PASI score >10
•No treatment or stable treatment of psoriasis during at least 3 months before inclusion
•Steady weight through 3 months with a body mass index (BMI) above 27 kg/m2
•Normal blood pressure
•Spiral or hormonal birth control for fertile women during the entire treatment period and at least 3 days after the end of the treatment period (~5 times the plasma half-life)

Exclusion criteria

•Psoriasis arthritis
•Fasting plasma glucose > 7.5 mmol/L or HbA1c > 7.5%
•Type 1 diabetes
•Treatment for type 2 diabetes with GLP-1-based medicine (DDP-4-inhibitors or GLP-1-receptor-agonists)
•Heart failure, NYHA class III-IV
•Uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine >150 µM and/or albuminuria
•Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) >2 x upper normal serum levels)
•Anaemia
•Acute or chronic pancreatitis
•Struma or thyroid cancer
•Pregnancy or breast feeding
•Inability to complete the study

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Cardiometabolic biomarkers
1
Patient-reported / QoL
1
Other clinical outcomes
1
Other (unclassified)
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Body mass index

Time frame:Baseline and after 2 months

BMI, change

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

CRP

Time frame:Baseline and after 2 months

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Patient-reported / QoL

1 endpoint
Primary/protocol endpoint

DLQI (dermatology life quality index)

Time frame:Baseline and after 2 months

change from baseline, improvement

Other clinical outcomes

1 endpoint
Primary/protocol endpoint

PASI (psoriasis area and severity index)

Time frame:Baseline and after 2 months

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Skin biopsies

Time frame:Baseline and after 2 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.